Most importantly, management was carried out at the time of CIP onset and we believe that careful CIP management, especially early detection and treatment, will ease the attainment of the maximum clinical efficacy from anti‐PD‐1 antibody monotherapy. The gene discussed is PDCD1; the disease is hereditary sensory and autonomic neuropathy.